Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.
about
Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve MiceSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesAdverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virusCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxImmune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceHuman CD4+ T cell epitopes from vaccinia virus induced by vaccination or infectionPotential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization.A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.The poxvirus A35 protein is an immunoregulatorT cell inactivation by poxviral B22 family proteins increases viral virulence.Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infectionGender effects on humoral immune responses to smallpox vaccine.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Epithelial immunization induces polyfunctional CD8+ T cells and optimal mousepox protection.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Obligatory requirement for antibody in recovery from a primary poxvirus infectionN1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.Smallpox vaccines: targets of protective immunity.MHC class II-alpha chain knockout mice support increased viral replication that is independent of their lack of MHC class II cell surface expression and associated immune function deficiencies.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.How to design effective vaccines: lessons from an old success storyEctromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.Cowpox virus induces interleukin-10 both in vitro and in vivoPoxvirus-encoded gamma interferon binding protein dampens the host immune response to infectionBioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpoxCharacterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection modelDNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon responseComparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicityLoss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo.Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.CD8 T cells are essential for recovery from a respiratory vaccinia virus infection.Functional paralysis of GM-CSF-derived bone marrow cells productively infected with ectromelia virus.Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.The orchestrated functions of innate leukocytes and T cell subsets contribute to humoral immunity, virus control, and recovery from secondary poxvirus challengeDisparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
P2860
Q27316583-5F9332EB-F766-4A5C-8053-61B063542B21Q27325586-54E515FD-2D7C-4292-9B84-108CE322B018Q27346800-7D66975A-53F3-4067-8BA0-B44AA91C9FAAQ27346933-A57D12BE-D349-4E35-8D97-696ACD3759F1Q28748570-B805BE07-C852-4A10-9E86-92B2CDD7C709Q33302672-D3E7EA48-A58B-4C55-B32C-371177B053B4Q33373833-E7E05F3D-38D7-4AD0-B15C-C767AC444425Q33429965-D3B69C66-3077-4A43-928C-D7598BFD5E3EQ33558734-A7BBE400-EDD8-4F99-8272-50D93ACD5951Q33618867-1E2C33E0-847D-49A2-A2DB-B722311A0BDDQ33625383-695E629F-3D34-41D9-B65D-6117717E9AECQ33701473-816FCCA6-B424-4D88-9AD9-441C04906A1CQ33936717-BE701213-8ED6-4BB9-99F0-CB7F224BD7C1Q34059189-E18D348E-4127-485A-8BEF-8315F266E3B8Q34126697-EF8FC163-8ED4-4B89-BC6F-B7F2ACE8CB86Q34447009-C8D7230D-92B9-4E01-8B57-0F6D648F783FQ34717009-D2884920-60E8-4148-B76A-0507D95FAA32Q34742613-9E8149B3-2DDF-4C84-B77B-88C90914E465Q34780607-362EAB33-DBA4-4C7C-B7A1-3DAB14C014AEQ34808839-C03AAD3A-E31E-4F5E-8661-48227E95684DQ34910424-4D125262-EAAC-4DC5-B413-83A1E7783A2FQ34991389-8BD6D8D0-43B9-4AC9-879D-FF4512771F3BQ35118610-F476466E-B965-41EF-92A9-BA594C21F8C4Q35261304-3EDF8EDA-0354-4968-9AEB-72DAB17E9067Q35539329-BDA55DCC-13D6-44F5-82AD-ACB3046D3B32Q35784998-2D03C4E8-8540-4617-8578-17042E6ED974Q35909727-482E0828-05B3-4CEB-A3B2-DE7A1CFAE453Q35948047-F6369B0E-7CE9-4D1B-817C-05BC40ECCE72Q36129034-9189579E-B6EB-4417-90C7-6D599804462DQ36130201-9590D61E-729F-448B-A915-2C51FE747FB1Q36155001-82CF10B0-4AFD-46CD-A941-55FA6E56CD17Q36155548-856E7B3F-8304-46A7-AD82-03E6D2097D85Q36155569-EAC6FBDB-871B-4A70-9D1C-54C271ECC637Q36172531-E56E81FA-6E58-4B88-A549-D063A286E5CFQ36394928-E70BB7EE-DDFE-4926-AB88-B848E07125B3Q36399165-060FEE1C-461A-41EB-BEC2-79BB62D8BDDBQ36488876-51C46BBF-EA61-4519-957B-5327CA5BC44AQ36559636-30E5AFEA-7E75-4E6E-898B-3AEDE1D2E423Q36759794-54D5B2EB-A0A8-4A63-81BB-89CDE58E934AQ36845650-1A0E9171-DBC1-455D-B8D1-33CD065E2424
P2860
Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@ast
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@en
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@nl
type
label
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@ast
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@en
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@nl
prefLabel
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@ast
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@en
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@nl
P2093
P2860
P356
P1433
P1476
Protective immunity against se ...... on CD4 or CD8 T-cell function.
@en
P2093
Geeta Chaudhri
Gunasegaran Karupiah
Vijay Panchanathan
P2860
P304
P356
10.1128/JVI.00115-06
P407
P577
2006-07-01T00:00:00Z